Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma

BACKGROUND: Circulating tumor DNA (ctDNA) is a biomarker for the selection of target agents in various malignancies. In this study, we examined the effect of ctDNA presence on the response to EGFR‐tyrosine kinase inhibitor (TKI) and on the prognosis in lung adenocarcinoma. METHODS: ctDNA of EGFR‐TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Taehee, Kim, Eun Young, Lee, Sang Hoon, Kwon, Do Sun, Kim, Arum, Chang, Yoon Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885440/
https://www.ncbi.nlm.nih.gov/pubmed/31647198
http://dx.doi.org/10.1111/1759-7714.13219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885440/
https://www.ncbi.nlm.nih.gov/pubmed/31647198
http://dx.doi.org/10.1111/1759-7714.13219

Ejemplares similares